122 148
prediction of muscle-invasive and non-organ con
fi
ned disease in
patients with upper tract urothelial carcinoma. BJU Int 2012;109:
77
–
82
.
[50]
Seisen T, Colin P, Hupertan V, et al. Postoperative nomogram to predict cancer-speci fi c survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothe- lial carcinoma without metastasis. BJU Int 2014;114:733 – 40.
[51]
Roupret M, Hupertan V, Seisen T, et al. Prediction of cancer speci fi c survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. J Urol 2013;189:1662 – 9.[52]
Seisen T, Granger B, Colin P, et al. A systematic review and meta- analysis of clinicopathologic factors linked to intravesical recur- rence after radical nephroureterectomy to treat upper tract urothe- lial carcinoma. Eur Urol 2015;67:1122 – 33.
[53]
Marchioni M, Primiceri G, Cindolo L, et al. Impact of diagnostic ureteroscopy on intra vesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis. BJU Int 2017;120:313 – 9.[54]
Seisen T, Peyronnet B, Dominguez-Escrig JL, et al. Oncologic out- comes of kidney-sparing surgery versus radical nephroureterec- tomy for upper tract urothelial carcinoma: a systematic review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. Eur Urol 2016;70:1052 – 68.[55]
Cutress ML, Stewart GD, Zakikhani P, Phipps S, Thomas BG, Tolley DA. Ureteroscopic and percutaneous management of upper tract urothe- lial carcinoma (UTUC): systematic review. BJU Int 2012;110:614 – 28.[56]
Villa L, Cloutier J, Letendre J, et al. Early repeated ureteroscopy within 6-8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary fi ndings. World J Urol 2016;34:1201 – 6.
[57]
Lughezzani G, Jeldres C, Isbarn H, et al. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer 2009;45:3291 – 7.[58]
Colin P, Ouzzane A, Pignot G, et al. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterec- tomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. BJU Int 2012;110:1134 – 41.[59]
Giannarini G, Kessler TM, Birkhauser FD, Thalmann GN, Studer UE. Antegrade perfusionwith bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may bene fi t? Eur Urol 2011;60:955 – 60.[60]
Xylinas E, Rink M, Cha EK, et al. Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 2014;65:210 – 7.[61]
Xylinas E, Kluth L, Passoni N, et al. Prediction of intravesical recur- rence after radical nephroureterectomy: development of a clinical decision-making tool. Eur Urol 2014;65:650 – 8.[62]
Ni S, Tao W, Chen Q, et al. Laparoscopic versus open nephro- ureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of com- parative studies. Eur Urol 2012;61:1142 – 53.
[63]
Ariane MM, Colin P, Ouzzane A, et al. Assessment of oncologic control obtained after open versus laparoscopic nephroureterec- tomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study. Ann Surg Oncol 2012;19:301 – 8.[64]
Adibi M, Youssef R, Shariat SF, et al. Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. Int J Urol 2012;19:1060 – 6.[65]
Rodriguez JF, Packiam VT, Boysen WR, et al. Utilization and out- comes of nephroureterectomy for upper tract urothelial carcinoma by surgical approach. J Endourol 2017;31:661 – 5.
[66]
Aboumohamed AA, Krane LS, Hemal AK. Oncologic outcomes fol- lowing robot-assisted laparoscopic nephroureterectomy with blad- der cuff excision for upper tract urothelial carcinoma. J Urol 2015;194:1561 – 6.
[67]
Moschini M, Foerster B, Abufaraj M, et al. Trends of lymphadenec- tomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. World J Urol 2017;35:1541 – 7.
[68]
O ’ Brien T, Ray E, Singh R, Coker B, Beard R. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clin- ical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 2011;60:703 – 10.[69]
Ito A, Shintaku I, Satoh M, et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol 2013;31:1422 – 7.
[70]
Fang D, Li XS, Xiong GY, Yao L, He ZS, Zhou LQ. Prophylactic intravesical chemotherapy to prevent bladder tumors after neph- roureterectomy for primary upper urinary tract urothelial carcino- mas: a systematic review and meta-analysis. Urol Int 2013;91: 291 – 6.
[71]
Matin SF, Margulis V, Kamat A, et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 2010;116:3127 – 34.[72]
Seisen T, Jindal T, Karabon P, et al. Ef fi cacy of systemic chemotherapy plus radical nephroureterectomy for metastatic upper tract urothe- lial carcinoma. Eur Urol 2017;71:714 – 8.
[73]
Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J. A systematic review and meta-analysis of adjuvant and neoadju- vant chemotherapy for upper tract urothelial carcinoma. Eur Urol 2014;66:529 – 41.
[74]
Seisen T, Krasnow RE, Bellmunt J, et al. Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally ad- vanced and/or positive regional lymph node upper tract urothelial carcinoma. J Clin Oncol 2017;35:852 – 60.[75]
Ploussard G, Xylinas E, Lotan Y, et al. Conditional survival after radical nephroureterectomy for upper tract carcinoma. Eur Urol 2015;67:803 – 12.
[76] Shigeta K, Kikuchi E, Hagiwara M, et al. The over time conditional
survival of intravesical recurrence in upper tract urothelial carcinoma.
J Urol. In press.
http://dx.doi.org/10.1016/j.juro.2017.06.073.
E U R O P E A N U R O L O GY 7 3 ( 2 0 18 ) 111
–
1 2 2
122